N-[(2R,3R,4R,5S,6R)-4-Hydroxy-6-(hydroxymethyl)-2-[(2R,3S,4R,5R)-1,3,4,5,6-pentahydroxyhexan-2-yl]oxy-5-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-3-yl]acetamide

Term ID

CHEBI:150908

Synonyms

Definition

References

glytoucan:G44318GH

Ontology

ChEBI ( EBI )

Relationships

Phenotype

Phenotype resulting from N-[(2R,3R,4R,5S,6R)-4-Hydroxy-6-(hydroxymethyl)-2-[(2R,3S,4R,5R)-1,3,4,5,6-pentahydroxyhexan-2-yl]oxy-5-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-3-yl]acetamide

Phenotype where environments contain N-[(2R,3R,4R,5S,6R)-4-Hydroxy-6-(hydroxymethyl)-2-[(2R,3S,4R,5R)-1,3,4,5,6-pentahydroxyhexan-2-yl]oxy-5-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-3-yl]acetamide

Phenotype modified by environments containing N-[(2R,3R,4R,5S,6R)-4-Hydroxy-6-(hydroxymethyl)-2-[(2R,3S,4R,5R)-1,3,4,5,6-pentahydroxyhexan-2-yl]oxy-5-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-3-yl]acetamide

Phenotype affecting N-[(2R,3R,4R,5S,6R)-4-Hydroxy-6-(hydroxymethyl)-2-[(2R,3S,4R,5R)-1,3,4,5,6-pentahydroxyhexan-2-yl]oxy-5-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-3-yl]acetamide

Human Disease Model